Kinase Inhibitors and Ovarian Cancer

Ovarian cancer is fifth in the rankings of cancer deaths among women, and accounts for more deaths than any other gynecological malignancy. Despite some improvement in overall-(OS) and progression-free survival (PFS) following surgery and first-line chemotherapy, there is a need for development of n...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2019-09, Vol.11 (9), p.1357
Main Authors: Katopodis, Periklis, Chudasama, Dimple, Wander, Gurleen, Sales, Louise, Kumar, Juhi, Pandhal, Manreen, Anikin, Vladimir, Chatterjee, Jayanta, Hall, Marcia, Karteris, Emmanouil
Format: Article
Language:English
Subjects:
Angiogenesis
Apoptosis
Cancer therapies
Cell cycle
Cell growth
Chemotherapy
Clinical trials
Fallopian tubes
Gynecology
Immunotherapy
Kidney cancer
Kinases
Liver cancer
Malignancy
Medical prognosis
Obstetrics
Ovarian cancer
Patients
Phosphorylation
Protein-tyrosine kinase
Proteins
Rapamycin
Review
Signal transduction
Surgery
Thyroid cancer
TOR protein
Tumors
Vascular endothelial growth factor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ovarian cancer is fifth in the rankings of cancer deaths among women, and accounts for more deaths than any other gynecological malignancy. Despite some improvement in overall-(OS) and progression-free survival (PFS) following surgery and first-line chemotherapy, there is a need for development of novel and more effective therapeutic strategies. In this mini review, we provide a summary of the current landscape of the clinical use of tyrosine kinase inhibitors (TKIs) and mechanistic target of rapamycin (mTOR) inhibitors in ovarian cancer. Emerging data from phase I and II trials reveals that a combinatorial treatment that includes TKIs and chemotherapy agents seems promising in terms of PFS despite some adverse effects recorded; whereas the use of mTOR inhibitors seems less effective. There is a need for further research into the inhibition of multiple signaling pathways in ovarian cancer and progression to phase III trials for drugs that seem most promising.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers11091357